Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 6, 2014, Pages 776-780

  Nishihori, Taiga ^a   Perkins, Janelle ^a   Mishra, Asmita ^a   Komrokji, Rami ^a   Kim, Jongphil ^a   Kharfan Dabaja, Mohamed A ^a   Perez, Lia ^a   Lancet, Jeffrey ^a   Fernandez, Hugo ^a   List, Alan ^a   Anasetti, Claudio ^a   Field, Teresa ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

5 Azacitidine; Allogeneic hematopoietic cell transplantation; Hypomethylating agent; MDS

Indexed keywords

AZACITIDINE; BUSULFAN; FLUDARABINE;

ABSCESS; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HLA MATCHING; HUMAN; LUNG MYCOSIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; ORGAN DONOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE; UNRELATED DONORS; YOUNG ADULT; ALLOTRANSPLANTATION; CLINICAL TRIAL; DONOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROMES; PILOT STUDY; PROCEDURES; PROSPECTIVE STUDY;

ADULT; AGED; AZACITIDINE; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; PROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84899981603     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.02.008     Document Type: Article

References (29)

1. Nimer S.D. Myelodysplastic syndromes. Blood 2008, 111:4841-4851.
2. Silverman L.R., McKenzie D.R., Peterson B.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-3903.
3. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
4. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579-585.
5. Issa J.P. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Nature Clin Pract Oncol 2005, 2(Suppl 1):S24-S29.
6. Kim D.Y., Lee J.H., Park Y.H., et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant 2012, 47:374-379.
7. Damaj G., Duhamel A., Robin M., et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. J Clin Oncol 2012, 30:4533-4540.
8. Platzbecker U., Schetelig J., Finke J., et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant 2012, 18:1415-1421.
9. Field T., Perkins J., Huang Y., et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010, 45:255-260.
10. De Padua Silva L., de Lima M., Kantarjian H., et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009, 43:839-843.
11. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
12. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
13. Cheson B.D., Bennett J.M., Kantarjian H., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
14. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
15. Perkins J.B., Kim J., Anasetti C., et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1099-1107.
16. Pidala J., Tomblyn M., Nishihori T., et al. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1237-1244.
17. Perkins J., Field T., Kim J., et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010, 16:937-947.
18. Pidala J., Kim J., Jim H., et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012, 97:1882-1889.
19. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
20. Gray R.J. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
21. Choudhury J.B. Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 2002, 21:1129-1144.
22. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
23. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
24. Lübbert M., Bertz H., Rüter B., et al. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009, 44:585-588.
25. Cogle C.R., Imanirad I., Wiggins L.E., et al. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol 2010, 8:40-46.
26. Gerds A.T., Gooley T.A., Estey E.H., et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012, 18:1211-1218.
27. Lübbert M., Bertz H., Müller M.J., Finke J. When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome/acute myeloid leukemia. J Clin Oncol 2013, 31:822-823.
28. Prébet T., Gore S.D., Esterni B., et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011, 29:3322-3327.
29. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010, 116:5420-5431.